CyanVac LLC
CyanVac LLC is a biotechnology company focused on developing intranasal vaccines for the prevention of viral and other infectious diseases. Using a parainfluenza virus 5 (PIV5)-based platform, the company aims to provide vaccines that are easy to administer, transport, and manufacture, supporting broad global access. The company has multiple clinical and preclinical vaccine candidates targeting diseases such as COVID-19, RSV, pandemic influenza, norovirus, and Lyme disease. CyanVac's platform emphasizes the creation of mucosal immunity to block disease transmission and address vaccine hesitancy, particularly among those averse to needle-based delivery.
Industries
N/A
Products
A clinical-stage intranasal vaccine candidate targeting COVID-19, designed to generate mucosal immunity and reduce transmission.
An intranasal, live vaccine expressing RSV F-protein, in development for children and adults, with Phase 1 and 1/2 clinical studies ongoing.
Intranasal vaccines developed for H5N1 and H7N9 influenza, shown to protect against these in animal models with potential for self-administration.
Preclinical-stage intranasal vaccine against norovirus developed with PIV5 platform.
Preclinical-stage vaccine developed using PIV5-vectored platform for the prevention of Lyme disease.
A clinical-stage intranasal vaccine candidate targeting COVID-19, designed to generate mucosal immunity and reduce transmission.
An intranasal, live vaccine expressing RSV F-protein, in development for children and adults, with Phase 1 and 1/2 clinical studies ongoing.
Intranasal vaccines developed for H5N1 and H7N9 influenza, shown to protect against these in animal models with potential for self-administration.
Preclinical-stage intranasal vaccine against norovirus developed with PIV5 platform.
Preclinical-stage vaccine developed using PIV5-vectored platform for the prevention of Lyme disease.
Expertise Areas
- Intranasal vaccine development
- Viral vector engineering
- Preclinical and clinical trial management
- Immunology and virology assay development
Key Technologies
- Parainfluenza virus 5 (PIV5)-based vectors
- Intranasal spray delivery
- Bioreactor-based vaccine manufacturing
- Immunogenicity assays (ELISA, neutralization, flow cytometry, etc.)
Key People
Chief Executive Officer
Chief Financial Officer
Chief Scientific Officer
Chief Business Officer
SVP, Program Management and Contracts
Chief Medical Officer
Chief Executive Officer
Chief Financial Officer
Chief Scientific Officer
Chief Business Officer
SVP, Program Management and Contracts
Chief Medical Officer